Kidney Selective AMPK Activators to Treat Polycystic Kiney Disease

Information

• Research Project
• 8646478

• ApplicationId

  8646478

• Core Project Number

  R43DK098959

• Full Project Number

  1R43DK098959-01A1

• Serial Number

  098959

• FOA Number

  PA-13-088

• Sub Project Id

• Project Start Date

  9/16/2013 - 11 years ago

• Project End Date

  6/30/2014 - 10 years ago

• Program Officer Name

  MOXEY-MIMS, MARVA M.

• Budget Start Date

  9/16/2013 - 11 years ago

• Budget End Date

  6/30/2014 - 10 years ago

• Fiscal Year

  2013

• Support Year

  01

• Suffix

  A1

• Award Notice Date

  9/19/2013 - 10 years ago

Organizations

• NOVATARG, INC.

DESCRIPTION (provided by applicant): There are approximately 12 million people suffering from autosomal dominant polycystic kidney disease (ADPKD) worldwide. ADPKD is a chronic condition with no effective drug therapies available; dialysis and transplantation are performed at costs of >$2 billion/year in the US. NovaTarg has developed a novel and kidney selective approach to PKD treatment which is expected to generate drugs that block underlying disease processes and to provide innovative therapies for PKD patients.

IC Name

• Activity

  R43

• Administering IC

  DK

• Application Type

  1

• Direct Cost Amount

• Indirect Cost Amount

• Total Cost

  415078

• Sub Project Total Cost

• ARRA Funded

  False

• CFDA Code

  847

• Ed Inst. Type

• Funding ICs

  NIDDK:415078\

• Funding Mechanism

  SBIR-STTR RPGs

• Study Section

  ZRG1

• Study Section Name

  Special Emphasis Panel

• Organization Name

  NOVATARG, INC.

• Organization Department

• Organization DUNS

  962942863

• Organization City

  Research Triangle Park

• Organization State

  NC

• Organization Country

  UNITED STATES

• Organization Zip Code

  277090003

• Organization District

  UNITED STATES